Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Equity Average (2017 - 2025)

Anaptysbio filings provide 9 years of Equity Average readings, the most recent being $3.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 94.98% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, down 94.98%, and an annual FY2025 reading of $54.0 million, down 32.01% over the prior year.
  • Equity Average hit $3.9 million in Q4 2025 for Anaptysbio, up from -$37.1 million in the prior quarter.
  • The five-year high for Equity Average was $389.3 million in Q1 2021, with the low at -$37.1 million in Q3 2025.
  • Median Equity Average over the past 5 years was $152.1 million (2023), compared with a mean of $181.0 million.
  • The sharpest move saw Equity Average increased 3.73% in 2021, then tumbled 178.68% in 2025.
  • Year by year, Equity Average stood at $370.0 million in 2021, then fell by 27.07% to $269.9 million in 2022, then crashed by 61.37% to $104.2 million in 2023, then fell by 25.54% to $77.6 million in 2024, then plummeted by 94.98% to $3.9 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $3.9 million, -$37.1 million, and -$5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.